Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Pioneering Unprecedented Life-Saving Equipment: Intelligent Aortic Balloon Catheter for Cardiac Arrest

Project description

Small balloon tech is a big step in cardiac care

Cardiac arrest remains a leading cause of death, with survival rates especially low for patients who cannot be treated with a defibrillator – about 76 % of cases. For these individuals, the likelihood of leaving the hospital alive is just 3.3 %. In this context, the EIC-funded PULSE project supports the market entry of a breakthrough solution: the Neurescue device. It is an intelligent aortic balloon catheter that increases blood flow to the heart and brain during resuscitation, dramatically improving survival odds – potentially by up to 40 %. Crucially, it works without fluoroscopy and outside hospital settings. PULSE will help Neurescue secure clinical validation, aiming to bring this technology to patients by 2027.

Objective

With a worldwide incidence expected to increase from 9 million cases in 2023 to 11 million cases by 2030, cardiac arrest is a public health crisis with a survival rate at only around 10% and a high degree of brain damage among the few survivors. Defibrillators cannot be used in 76% of cardiac arrest patients due to a non-shockable rhythm, leading to an extremely low survival-to-discharge for these patients (3.3%).
Neurescue Aps (NEUR) addresses the cardiac arrest burden by bringing to market a game-changing solution – the Neurescue device – the world's first intelligent fluoroscopy-free aortic balloon catheter. By combining unique proprietary features including 1) an intelligent system for automated balloon inflation and deflation managed by the controller component, coupled with 2) precise positioning feedback from the patented sensor system in the catheter, these together provide a safe computer-controlled aortic balloon occlusion for use both inside and outside hospital settings.
The Neurescue device increases blood flow to the heart and brain, which makes the patient more likely to respond to resuscitation efforts. This also increases the likelihood of bridging patients to definitive therapies, extending the critical time window from the current 20-30 min to ~60 min. This is especially valuable in patients with a non-shockable rhythm for whom the standard of care (SoC) results in extremely low survival (3.3%). The use of the Neurescue device, both inside and outside hospitals, is expected to increase the survival rate of cardiac patients by up to 40% - thereby holding the potential to save millions of lives.
The Neurescue device is projected to be ready for commercial roll-out by 2027 reaching €931.37M in revenues by 2033. The PULSE project aims to surpass the main market barriers associated with the market introduction of the Neurescue device, namely gathering data for a CE mark and clinical validation to ensure end-user adoption

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC - HORIZON EIC Accelerator

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-ACCELERATOR-02

See all projects funded under this call

Coordinator

NEURESCUE APS
Net EU contribution
€ 2 499 999,00
Address
NJALSGADE 76
2300 Kobenhavn
Denmark
SME
Yes
Region
Danmark Hovedstaden Byen København
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data